Introducing CD5 into CD5 -B cells induces the production of IL-10 by activating its promoter and the synthesis of its mRNA. The cytoplasmic domain of CD5 is sufficient for this process.
CD5 also protects normal human B cells from apoptosis after BCR stimulation while reducing BCR-induced Ca 2+ response. We conclude that CD5 supports the survival of B cells by stimulating IL-10 production and by exerting concurrently a negative feedback on BCRinduced signaling events that can promote cell death.
Introduction
CD5 is a lymphoid marker and one of the earliest acquired during T cell ontogeny. Its expression increases coordinately with that of cell surface CD3 (1) . While expressed on lymphoid-committed progenitors, its expression is however lost following NK cell differentiation (2) . In contrast to being a pan-T cell marker, CD5 is only expressed on some B cells, and on the basis of its coexpression with CD11b, IgM+ B cells in mouse and human are classicaly separated into different subsets termed B-1a, B-1b -both expressing CD11b-and B-2 (3). The B-1a subset expresses CD5, and at a functional level these CD5 + B cells frequently produce polyreactive antibodies, mainly IgM, which recognize a variety of self and foreign antigens (4) . The reason for the expression of CD5, "one of many intriguing and seemingly idiosyncratic features of B-1a cells" (5), on a particular B-cell subset remained obscure. Two hypothesis are proposed to explain the origin of B-1 cells. The lineage hypothesis holds that only certain fetal progenitors are destined to become B-1 cells (6, 7) . In contrast, the differentiation hypothesis holds that every B cell is able to acquire B-1 cell characteristics. In brief, the notion of B cell lineages based on differential CD5 expression is controversial due to the clear identification of a fetal progenitor destined to become a B-1 B cell and the demonstration that CD5 -cells can acquire CD5 expression in vivo (8) or in vitro (9) , following BCR stimulation This upregulation supports the initial view that CD5 is an activation marker (10) , however a definitive function for this antigen had still to be established.
It has been shown that CD5 upregulation in B cells plays a role in tolerance to autoantigens.
By setting the threshold level for activation signals, CD5 prevents B cells from activationinduced cell death and maintains tolerance in anergic B cells in vivo (11) . The reason for keeping potentially auto-reactive cells alive is that these cells are also necessary for an effective immune response to some pathogens (12) . This supported the role of CD5 as a
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 4 negative regulator of BCR-signaling, which was later demonstrated by the generation of CD5-null mice (13) . In these animals, peritoneal B cells, which are poorly responsive to BCR stimulation, restored their capacity to fully proliferate to anti-IgM (13).
The molecular basis for BCR inhibition by CD5 has been extensively investigated. The physical association of CD5 to the BCR was demonstrated (14) and our recent work further documented the structural basis of CD5 inhibition of the BCR-mediated signals. Using a reconstitution approach, in a murine lymphoma B cell line, we have shown that Ca 2+ response, ERK-2 activation and the production of IL-2 induced by BCR activation were antagonized by CD5 (15) . The role of the src auto-phosphorylation-like motif within the cytoplasmic domain was demonstrated (16) . Of interest, this domain is highly conserved between mice and humans (3).
We investigated herein the role of CD5 in human B cells. We surmised that the either constitutive, or BCR-induced, expression of CD5 would play a role in B cell survival possibly through induction of cytokines. IL-10 is the most relevant cytokine for B cell survival both in mice and humans. In mice, unlike B-2 cells, CD5 + B-1 B cells are long-lived in vivo and in vitro (6, 7) . IL-10 is involved in the long-term maintenance of peritoneal B cells (17) , as it is produced mainly by B-1 cells, suggesting a positive autocrine regulatory loop (18, 19) .
However, the precise mechanism of IL-10 production remained unknown, and a possible direct relationship between CD5 expression and IL-10 secretion was never addressed. 
Methods

Cells and cell cultures
The human B lymphoma cell line Daudi was grown in RPMI 1640 medium (Seromed, Biochrom KG, Berlin, Germany) supplemented with 10% FCS, antibiotics (50U/ml penicillin, 50 µg/ml streptomycin), 2 mM L-glutamine, and 1mM sodium pyruvate (complete medium).
Daudi-LZRS and Daudi-LZRS.CD5 were grown in complete medium. Daudi-pNT.CD5 and Daudi-pNT.FcR-CD5 expressing a chimeric receptor made of the Fc RIIB1 extracellular and transmembrane domains fused to human CD5 cytoplasmic tail, were cultured in the same medium supplemented with 1 mg/ml G-418 (Geneticin, Invitrogen, Groningen, The Netherlands). This medium was also used for selection and culture of the pNT-neo vector stable transfectants (see below).
Peripheral B lymphocytes were obtained from blood donors with their informed consent.
Blood was centrifuged on Lymphocyte separation medium, density 1,077 (Eurobio, Les Ullis, 
Antibodies and reagents
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Ca 2+ response analysis Intracellular Ca 2+ measurements on cell suspensions were performed with Fura-2/AM (Molecular Probes, Eugene, OR) as described previously (13).
For Ca 2+ response and CD5 expression correlation experiments, purified B cells were placed on gridded coverslips (CELLocate, Eppendorf, Hamburg, Germany) allowing to mark the localization of individual cells. Single cell imaging was analyzed with a Diaphot 300 microscope (Nikon, Melville, NY) and an IMSTAR imaging system, as described previously (14) . After a 20-min Ca Analysis of IL-10 Promoter activity using the luciferase assay: The demonstration that CD5 antagonizes early signaling events mediated by the BCR was made in CD5-null mice (13) and by ourselves in murine cell lines (14, 15) . We investigated whether this was true in human blood B cells. Our experiments were based on negative purification of B cells instead of CD19-based sorting, to avoid any signaling through CD19 molecule (24) . Unfractionnated (>90% pure) B cells were allowed to settle on a gridded coverslip and stimulated with anti-IgM, and Ca 2+ response analyzed with an imaging system.
Thereafter, cells were stained on coverslips with anti-CD5 mAb, fixed, and CD5 expression revealed by microscopy. An example is illustrated in Figure 3 , showing a Ca These results show that the basal calcium level, albeit slightly higher in CD5 + cells (82.7 ± 37.8 vs 68.9 ± 36.9), is not significantly different between the two B cell populations.
Thus, as in B-1a murine B cells, CD5 is also a negative regulator of BCR signaling in peripheral blood human B cells.
Introduction of CD5 into Daudi cells inhibits BCR signaling and triggers IL-10
production.
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The results were similar with whole anti-IgM Ab (data not shown). Anti-IgM induced the production of IL-10 in a dose-response manner, reaching a plateau for 1-2 µg/ml of F(ab') 2 . Interestingly, most of the increment in IL-10 production was observed with 0,5 µg/ml of F(ab') 2 , however the slope was steeper in CD5-transfected than in vector-transfected cells.
Thus CD5-transfected cells reach a plateau for IL-10 production with less anti-IgM than vector-transfected cells. One interpretation is that CD5 has a synergistic effect on BCR- For 
CD5 and peripheral B cell survival
It has been shown that a strong BCR-mediated activation ultimately leads to programmed cell death (25) . Meanwhile, CD5, which is upregulated following BCR engagement, exerts a negative feedback on the BCR thus contributing to B cell survival. On the other hand IL-10 was shown to promote B cell survival (17) (18) (19) . Our above results suggested that IL-10 may also contribute to the enhancement of B cell survival mediated by CD5 upregulation. We tried here to address the physiological relevance of our observations by studying BCR-mediated cell death in peripheral blood B cells. We activated B cells and cultured them in medium alone or with neutralizing anti-IL-10 antibodies (Figure 7) . Using a reconstitution approach, we showed that CD5 also exerted a positive effect on BCR- Moreover, culturing the cells with mAb against the CD5 molecule or against CD72 -a putative CD5 ligand-has no influence on IL-10 production (unpublished data).
A second evidence suggesting that, in this cellular model, CD5 has a direct influence on IL-10 production independently of BCR stimulation came from studies on the IL-10 promoter. We found that an anti-IgM stimulation failed to further increase the activity induced by CD5.
Nevertheless anti-IgM stimulation increased IL-10 mRNA (not shown) and protein production in CD5-transduced cells suggesting that while CD5 directly enhances IL-10 transcription, BCR mediates its effect at a post-transcriptional level, possibly by stabilizing mRNA. How CD5 works to activate the IL-10 promoter is not yet understood and it should be emphasized here that we have presented no evidence that CD5 can also directly influence the activity of this promoter in normal B cells. We could speculate that, since the promoter is already significantly activated in Daudi B cells, it would be highly sensitive to additive signal
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From triggered by CD5. The nature of this signal is unknown. However, although CD5 is not significantly phosphorylated on tyrosine residues in unstimulated Daudi cells (not shown), likely excluding a role for SH2 domain-containing proteins in the observed phenomenon, the CD5 cytoplasmic domain can also recruit signaling molecules independently of BCR stimulation (27, 28) . This situation may be achieved in activated normal B cells that have upregulated the CD5 molecule or in CD5 + B cell subsets that produce IL-10, such as the one in the peritoneum (17) (18) (19) .
An important issue is therefore to understand the molecular mechanisms governing CD5 expression, inasmuch as contrary to BCR, other signals than such as those induced by EBV, are able to modulate CD5 expression (10) . It could be argued that the distinction between CD5 positive and negative subsets is an artifact as all B cells seem to express little CD5 if analyzed by using an amplification technique (10) . This however does not raise question about our results since we showed that normal human peripheral B cells that up-regulate CD5 also up-regulate IL-10 in parallel, making our results applicable to all B cells. The respective roles of BCR and CD5 in IL-10 production could not be directly addressed in de novo CD5 + peripheral B cells, mainly because we were unable to dissociate CD5 expression from BCR stimulation, by using several inhibitors of BCR-signaling pathways (unpublished data).
Nevertheless, our transfected Daudi cell model demonstrate the direct role of CD5 in IL-10 production, inasmuch as activated Daudi cells failed to express endogenous CD5.
We think therefore that, by down-modulating BCR-signaling and up-regulating IL-10 production in parallel, CD5 uses these metabolic processes coordinately to control the fate of B cells in general, following antigen encounter, and that its expression may also explain the prolonged survival of human B cell subsets equivalent to B-1a cells in the mouse. Human B-1 B cells, albeit less well characterized than murine ones, are found in cord blood (29) , in adult blood (30) , and are enriched for cells that spontaneously produce polyreactive antibodies (4).
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In pathology, the prototypic disease with proliferation of CD5-positive cells is chronic lymphocytic leukemia. There is some evidence that malignant CLL cells belong to B-1 cells (31, 32) , and that IL-10 is an autocrine growth factor needed for the expansion of malignant B cells (32, 33) . This hypothesis is substantiated by the recent demonstration that de novo CD5 + diffuse large B-cell lymphomas are more aggressive than their CD5 -counterpart (34) . As a matter of fact, the role of IL-10 as an autocrine growth factor needed for the expansion of malignant B cells expressing the CD5 molecule may not be fortuitous.
